Wavelength Pharmaceuticals Acquires Vanamali Organics

The deal expands Wavelength’s drug substance manufacturing footprint and its API CDMO business.

Wavelength Pharmaceuticals, an Israel-based developer and manufacturer of APIs, announced on Feb. 18, 2021 that it acquired a majority stake in Vanamali Organics Pvt. Ltd. of Telangana, India. Vanamali manufactures pharmaceutical key starting materials and advanced drug intermediates. The deal expands Wavelength’s drug substance manufacturing footprint and its API contract development and manufacturing organization (CDMO) business.

“Our success in building a world-class operation supplying the highest quality APIs reflects our close alignment with the needs of our customers,” said Iftach Seri, CEO of Wavelength Pharmaceuticals, in the press release. “These include planning for an increasingly unpredictable world, where supply chain assurance and control of regulatory starting materials further back in the process have become a key strategic concern. Wavelength’s customers benefit from our three decades-long investment in creating the most robust supply chain in the industry.”

The acquisition of Vanamali Organics will add to Wavelength’s global supply chain network and its CDMO business. Vanamali Organics’ manufacturing capability ranges from small research quantities up to multi-ton commercial-scale production.

“As scientists who have spent the past decade building a science- and quality-focused research and manufacturing business, we welcome the opportunity to join forces with Wavelength,” said N. Sreenivasan, managing director of Vanamali Organics, in the press release.

Source: Wavelength Pharmaceuticals